GLP-1 side effects: how often they happen, how long they last and when to get help
GLP-1 side effects are mostly digestive. Nausea comes first, then diarrhea, vomiting, constipation and belly pain. In label trials, nausea affected 12% to 44% of people, depending on product and dose, mostly while doses were rising.1,2,3,4 Below are the label rates for Wegovy®, Ozempic®, Zepbound® and Mounjaro®, a timeline, what helps, and the rare problems that need a doctor or 911.
Using insurance? Check what your plan may cover.
Key points
- Most common: nausea, from 12% to 18% on Mounjaro up to 44% on Wegovy 2.4 mg.
- Timing: symptoms cluster around dose increases and ease on a steady dose.
- Rare but serious: pancreatitis, gallbladder problems, kidney injury, severe allergic reactions and NAION, a newly flagged eye condition.
- Boxed warning: not for people who have had medullary thyroid carcinoma, whose relatives have had it, or who have MEN 2.
What are the most common side effects of GLP-1 drugs?
Nausea tops the list of GLP-1 side effects, followed by diarrhea, vomiting, constipation and pain in the stomach area. These drugs slow how fast your stomach empties and act on brain areas that regulate appetite and nausea, which is why the gut takes the hit.1,5
The rates below come from each label’s placebo-controlled trials in adults, with the placebo rate underneath.
Swipe sideways to see all four medications.
| Symptom | Wegovy2.4 mg | Ozempic0.5 to 1 mg | Zepbound5 to 15 mg | Mounjaro5 to 15 mg |
|---|---|---|---|---|
| Nausea | 44%placebo 16% | 15.8 to 20.3%placebo 6.1% | 25 to 29%placebo 8% | 12 to 18%placebo 4% |
| Diarrhea | 30%placebo 16% | 8.5 to 8.8%placebo 1.9% | 19 to 23%placebo 8% | 12 to 17%placebo 9% |
| Vomiting | 24%placebo 6% | 5 to 9.2%placebo 2.3% | 8 to 13%placebo 2% | 5 to 9%placebo 2% |
| Constipation | 24%placebo 11% | 3.1 to 5%placebo 1.5% | 11 to 17%placebo 5% | 6 to 7%placebo 1% |
| Stomach pain | 20%placebo 10% | 5.7 to 7.3%placebo 4.6% | 9 to 10%placebo 5% | 5 to 6%placebo 4% |
Sources: each product’s prescribing information.1,2,3,4 Wegovy and Zepbound were tested for weight management. Ozempic and Mounjaro have FDA approval for type 2 diabetes, not weight loss, and were tested in diabetes trials. This is not a head-to-head comparison.
How to read these numbers
Who was studied matters as much as the dose. Zepbound and Mounjaro use identical tirzepatide doses, yet their rates differ. Placebo groups felt sick too: 16% of people on placebo in Wegovy’s trials reported nausea. Set against each drug’s own placebo group, the relative increase in many side effects looks similar for semaglutide and tirzepatide.5
Less common side effects
| Symptom | Wegovy2.4 mg | Zepbound5 to 15 mg |
|---|---|---|
| Fatigue | 11%placebo 5% | 5 to 7%placebo 3% |
| Hair loss | 3%placebo 1% | 4 to 5%placebo 1% |
| Injection site reactions | 1.4%placebo 1% | 6 to 8%placebo 2% |
Sources: Wegovy and Zepbound prescribing information.1,3
How long GLP-1 side effects last, and when they start
For most people, GLP-1 stomach side effects come in bouts during the first months, while the dose is climbing, and fade once it holds steady.3,5 No label gives a number of days.
Weekly GLP-1 injections start low and step up no faster than every 4 weeks. At that pace Wegovy reaches 2.4 mg in week 17 and Zepbound reaches 15 mg in week 21 at the earliest, so the first four to five months carry the most symptoms.1,3
Starting dose
A low dose lets your body adjust. Symptoms can still follow the first injection.3
Dose increases
Each step up can bring nausea, vomiting or diarrhea back for a while.1,3
Steady dose
Stomach symptoms decline.3 Gallstones and hair shedding are tied to the weight loss itself, not to dose changes.
What the trials recorded
- Mostly mild. In an analysis of semaglutide 2.4 mg trials, 99.5% of stomach side effects were not serious and 98.1% were mild to moderate.6
- Few people quit. 6.8% stopped Wegovy because of side effects (3.2% on placebo), and 4.8% to 6.7% stopped Zepbound (3.4%).1,3
If symptoms do not settle, tell your provider before the next increase. The Wegovy label allows a 4-week delay when a dose is not tolerated.1
Serious GLP-1 side effects and the warning signs to know
Serious side effects are uncommon, and most have warning signs you can act on. In Zepbound’s trials, acute kidney injury was reported by 0.5% of people (0.2% on placebo) and acute pancreatitis by 0.2% in both groups.3
| Possible problem | Warning signs | What to do |
|---|---|---|
| Pancreatitis | Severe stomach pain that will not let up, with or without vomiting, sometimes felt in the back | Stop the medication and call your provider at once |
| Gallbladder problems | Upper stomach pain, fever, yellowing of the skin or eyes, clay-colored stools | Contact your provider promptly |
| Dehydration and kidney injury | Vomiting or diarrhea that will not ease, or being unable to keep fluids down | Drink fluids and tell your provider right away |
| Low blood sugar | Dizziness, sweating, shakiness, confusion. Mainly with insulin or a sulfonylurea | Treat it as your provider showed you, then report it |
| Allergic emergency | Face, lips, tongue or throat swelling up, trouble breathing or swallowing, a severe rash | Stop the medication and call 911 |
| Sudden vision loss (NAION) | Painless loss of vision in one eye, or blurred or missing areas | Contact a healthcare professional right away |
Sources: product labels and the FDA.1,3,7
Call 911 or go to an emergency room if your face, lips, tongue or throat swell, you have trouble breathing or swallowing, or you faint. If you cannot reach your provider about severe stomach pain, get urgent in-person care.
Boxed warning: thyroid C-cell tumors
Semaglutide and tirzepatide cause thyroid C-cell tumors in rodents, and the risk in people is unknown. They are not for anyone with medullary thyroid carcinoma (MTC) in their own or their family’s history, or with MEN 2.1,3 See the safety information.
The new eye warning: NAION
On November 9, 2026, the FDA said it is requiring every GLP-1 label to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare cause of sudden, painless and sometimes permanent vision loss in one eye. Its analysis of 126 trials with 134,253 patients found 6.4 cases per 100,000 person-years on GLP-1 drugs and 3.8 on comparison treatments. As of November 18, 2026, the posted labels did not yet carry the wording.7
Before surgery or a procedure
Tell your surgical and anesthesia team that you take a GLP-1. The labels describe rare cases of stomach contents entering the lungs under anesthesia or deep sedation, even after fasting.1,3 Five medical societies advise that most patients can keep taking it before elective surgery, so do not skip a dose on your own.8
Mood, depression and suicidal thoughts
Wegovy, Zepbound and Saxenda® dropped their warnings about suicidal thoughts in 2026, after an FDA review of 91 placebo-controlled trials with 107,910 patients found no increased risk. The FDA still asks patients to report new or worsening depression. In a crisis, call or text 988.9
Side effects by GLP-1 medication
Every drug in the class shares the same core stomach side effects.
Semaglutide (Ozempic and Wegovy)
Semaglutide works through a single target, the GLP-1 receptor. Wegovy’s newer 7.2 mg dose shows what more drug does: nausea in 39% of people, against 35% on 2.4 mg and 13% on placebo, and changes in skin sensation in 22%, 6% and 0%.1 More: Wegovy, Ozempic and semaglutide side effects.
Tirzepatide (Mounjaro and Zepbound)
Tirzepatide targets both the GIP and GLP-1 receptors. SURMOUNT-5 compared it head to head with semaglutide for 72 weeks in 751 adults who had obesity. Digestive complaints led the side effect list for both drugs and were mostly mild to moderate.10
Birth control pills may work less well on tirzepatide, so the labels advise a non-oral or barrier method for 4 weeks after starting and after each dose increase.3,4 More: Zepbound, Mounjaro, tirzepatide and Mounjaro vs Ozempic.
GLP-1 pills
A tablet spares you injection site reactions, but not the stomach symptoms. Per its label, the Wegovy pill matched the 2.4 mg injection in the type and frequency of common side effects.1
Compounded semaglutide and tirzepatide
Compounded semaglutide and tirzepatide are not FDA-approved: the agency does not review their safety, effectiveness or quality. Every percentage on this page comes from trials of the approved products and cannot be assumed to apply to a compounded one.
As of May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide.11 It has also described overdoses of 5 to 20 times the intended dose from vials, after confusion between milliliters, milligrams and units.12 For the unit math, see tirzepatide dosing in units.
Managing GLP-1 side effects: what helps
Most stomach side effects ease with changes to how you eat, enough fluid and, when needed, a slower dose schedule. These tips come from a 2025 medical society advisory and from Wegovy’s maker.5,13 Ask your provider before adding an over-the-counter medicine.
Nausea and vomiting
Eat small meals every 3 to 4 hours, starting with a small breakfast, because large meals make vomiting more likely. Plain, low-fat choices (toast, rice, crackers) may help. Eat slowly and stay upright afterward. Ginger or peppermint tea can help too.5,13
Diarrhea
Skip large or high-fat meals and replace lost fluid.5 The labels warn that fluid loss can lead to kidney injury.1
Constipation
Drink enough and add fiber from food gradually, such as prunes. Fiber supplements and stool softeners are further options.5
Heartburn and bloating
Smaller, lower-fat meals are worth trying, since fat slows the stomach further. Alcohol can worsen reflux and nausea.5
Fatigue
Eating far less can leave you tired. Have regular small meals, protein first, and keep drinking.5
Injection site reactions
Change the spot every week, moving among the stomach area, thigh and upper arm.1
Ask about a slower schedule
Stepping up gradually limits how often and how badly symptoms hit.5 Holding or lowering a dose is your provider’s decision, so do not split or skip doses yourself.
Message your provider the same day if vomiting or diarrhea will not stop, you cannot keep fluids down, or a symptom keeps getting worse.
How Zealthy handles GLP-1 side effects
At Zealthy, a licensed provider sets the pace of your dose, and you can reach the care team between doses.
- Screening first. A U.S.-licensed physician or nurse practitioner reviews your health history and medications online. No live appointment is required.
- Slow dose increases. Your provider sets each step and can hold or lower your dose.
- Unlimited messaging. Secure messaging with the care team is included in membership.
- Optional visits. Monthly video or phone visits with a provider are there if you want one.
Zealthy providers prescribe brand-name Ozempic, Wegovy, Zepbound and Mounjaro, plus compounded semaglutide and tirzepatide, each only when appropriate. Compounded versions are not FDA-approved, and label percentages come from trials of the approved products. The membership costs $39 in the first month and $135 a month after that, and it does not include medication. In an emergency, call 911.
Long-term side effects of GLP-1 drugs
Long-term GLP-1 side effects are mostly consequences of major weight loss: muscle lost along with fat, gallstones, hair shedding and facial changes.
Muscle loss
Some of the weight lost is lean tissue. In a body-scan substudy of SURMOUNT-1 (160 adults, 72 weeks), about three quarters of the weight lost on tirzepatide was fat and one quarter lean mass, the same split as on placebo.14 The joint advisory says protein alone is unlikely to protect muscle without strength training.5
Gallstones
The Zepbound label links gallbladder problems to weight reduction. Gallbladder inflammation was reported by 0.7% of people on Zepbound and 0.2% on placebo.3
Hair shedding
Hair loss was reported by 7.1% of women and 0.5% of men on Zepbound, and the label ties it to weight reduction.3 Dermatologists believe sudden weight loss triggers the shedding.15
Changes in the face
“Ozempic face” is a nickname, not a label term. The American Academy of Dermatology says rapid weight loss is partly responsible for a less full, more lined face, and that GLP-1 drugs may also affect collagen and muscle.15
Weight regain after stopping
Regain is not a side effect, but plan for it. Participants in the STEP 1 trial who stopped semaglutide 2.4 mg after 68 weeks regained about two thirds of their lost weight within a year.16 Results vary.
Who should not take GLP-1 drugs?
Neither semaglutide nor tirzepatide is for you if medullary thyroid carcinoma runs in your family or you have had it yourself, if you have MEN 2, or if the drug has ever caused you a serious allergic reaction.1,3
They are not for weight loss during pregnancy, since the labels say the drug may harm the fetus, and semaglutide should be stopped at least 2 months before a planned pregnancy. They are not recommended with severe gastroparesis.1,3
Tell your provider first about pancreas problems, diabetic retinopathy, planned surgery, breastfeeding, and any insulin, sulfonylurea or other medicine taken by mouth, whose absorption can change.1,3 At Zealthy, a provider reviews this in your intake before prescribing.
GLP-1 side effects: common questions
Which GLP-1 side effect do people get most often?
Nausea leads on every label here: 44% of adults in Wegovy’s 2.4 mg trials, 25% to 29% in Zepbound’s, 15.8% to 20.3% in Ozempic’s and 12% to 18% in Mounjaro’s. Placebo groups reported it too, at 4% to 16%, so the drug is not behind every case.
Will GLP-1 side effects wear off, and how soon?
For most people they ease. Nausea, vomiting and diarrhea were most frequent while doses were being raised, which takes four to five months on Wegovy or Zepbound, and declined over time. If they persist, a provider can hold your dose for longer.
Is tirzepatide easier on the stomach than semaglutide?
Not clearly. Zepbound’s label rates are lower than Wegovy’s (nausea 25% to 29% against 44%), but the trials enrolled different people and their placebo rates differed too. In SURMOUNT-5, which compared the two directly, digestive side effects were the most common in both groups.
Can a GLP-1 make your hair fall out?
It can. Wegovy 2.4 mg trials recorded hair loss in 3% of people and Zepbound trials in 4% to 5%, against 1% on placebo, and women reported it far more often than men. Both labels describe it as associated with weight reduction.
Are there long-term side effects from taking a GLP-1 for years?
The main long-term concerns are losing muscle along with fat, gallstones, hair shedding and weight returning after you stop. The labels also have a boxed warning based on thyroid tumors in rodents, and a warning about the eye condition NAION is being added.
Why am I so tired on a GLP-1?
Fatigue is a listed side effect. Wegovy’s label reports it in 11% of people (placebo: 5%) and Zepbound’s in 5% to 7% (placebo: 3%). Eating far less than usual is a likely contributor. Tell your provider if it does not lift.
When should I go to the ER for GLP-1 side effects?
Call 911 or go to an emergency room for swelling of your face, lips, tongue or throat, trouble breathing or swallowing, or fainting. Severe stomach pain that will not let up means stopping the medication and calling your provider at once.
Do compounded semaglutide and tirzepatide have the same side effects?
Nobody can give you a rate. Compounded drugs are not FDA-approved, and the agency does not review their safety, effectiveness or quality. The percentages here come from trials of the four approved brands and cannot be assumed to apply to a compounded product.
Important safety information for GLP-1 medications
A summary of the prescribing information for Wegovy, Ozempic, Zepbound and Mounjaro. It does not replace the labels or your provider. Compounded semaglutide and tirzepatide are not FDA-approved.
Boxed warning: risk of thyroid C-cell tumors
Semaglutide and tirzepatide cause thyroid C-cell tumors in rodents. It is not known whether they cause these tumors, including medullary thyroid carcinoma (MTC), in people. Do not use them if you have had MTC, if a family member has, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
Do not use if
- You have had MTC, a family member has, or you have MEN 2.
- The medicine or one of its ingredients has caused you a serious allergic reaction.
Serious side effects
Pancreatitis, gallbladder problems, kidney injury from dehydration, severe stomach problems, low blood sugar (especially with insulin or a sulfonylurea), serious allergic reactions, vision changes including diabetic retinopathy complications and possibly NAION, and food or liquid entering the lungs during anesthesia.
Common side effects
Nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, fatigue and injection site reactions.
Other things to know
Ozempic and Mounjaro have FDA approval for type 2 diabetes only, not weight loss. Tell your provider if you are pregnant, breastfeeding or having surgery. Product safety sections: Wegovy, Zepbound, Ozempic, Mounjaro, semaglutide and tirzepatide. Report side effects to the FDA at 1-800-FDA-1088.
Sources
- Wegovy (semaglutide) Prescribing Information. Novo Nordisk. Revised June 2026. https://www.novo-pi.com/wegovy.pdf
- Ozempic (semaglutide) Prescribing Information. Novo Nordisk. Revised May 2026. https://www.novo-pi.com/ozempic.pdf
- Zepbound (tirzepatide) Prescribing Information. Eli Lilly. Revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf
- Mounjaro (tirzepatide) Prescribing Information. Eli Lilly. Revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity (Silver Spring). 2025;33(8):1475-1503. https://pubmed.ncbi.nlm.nih.gov/40445127/
- Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes Obes Metab. 2022;24(1):94-105. https://pubmed.ncbi.nlm.nih.gov/34514682/
- FDA. FDA requires safety labeling changes for GLP-1 receptor agonists due to potential increased risk of rare but serious eye condition. November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- American Society of Anesthesiologists. Most patients can continue diabetes, weight loss GLP-1 drugs before surgery. October 29, 2024. https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance
- FDA. FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist medications. 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
- FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- Novo Nordisk. Wegovy side effects. Accessed November 18, 2026. https://www.wegovy.com/taking-wegovy/side-effects.html
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(5):2720-2729. https://pubmed.ncbi.nlm.nih.gov/39996356/
- American Academy of Dermatology. How can GLP-1 drugs affect my skin, hair, and nails? February 17, 2026. https://www.aad.org/public/everyday-care/skin-care-secrets/prevent-skin-problems/glp1-drugs-and-side-effects
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
Start GLP-1 treatment with a provider who sets your pace
Answer a few health questions online. A licensed provider reviews them, and membership starts at $39 for the first month.

Side effects are easier with a provider you can reach
A licensed Zealthy provider reviews your health history and medications before prescribing, sets the pace of your dose increases and can slow them down. Between doses, the care team answers side effect questions by secure message and tells you when a symptom needs in-person care.
The medical information on this page is reviewed by the Zealthy care team against FDA prescribing information and published clinical trials. It is general education, not personal medical advice.
What Zealthy members say
One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
I started semaglutide at the recommendation of my Zealthy provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and Zealthy was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Since I started, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Individual results may vary. These are the experiences of Zealthy members and are not a guarantee of any outcome. Medication is prescribed only when a licensed provider finds it appropriate.
GLP-1 medications Zealthy providers can prescribe
Brand-name or compounded, a licensed provider decides what fits your health history. Our insurance team handles the prior authorization paperwork for brand-name medication.
Zepbound®
Tirzepatide, FDA-approved for weight management and for sleep apnea in adults with obesity.
Zepbound cost, savings card and side effects →Wegovy®
Semaglutide, FDA-approved for weight management, as a weekly injection or a daily pill.
Wegovy pill, cost and side effects →Mounjaro®
Tirzepatide, FDA-approved for type 2 diabetes. The same ingredient as Zepbound.
Mounjaro doses and savings card →Ozempic®
Semaglutide, FDA-approved for type 2 diabetes. Weight loss is an off-label use.
Ozempic side effects and cost →Compounded semaglutide
$199 a month, or from $106 a month on a 3-month supply, shipping included. Not FDA-approved.
Semaglutide cost and dosing →Compounded tirzepatide
$329 a month, or from $216 a month on a 3-month supply, shipping included. Not FDA-approved.
Tirzepatide dosage and cost →Compounded medications are prepared by a partner pharmacy for an individual prescription. They are not FDA-approved, which means the FDA has not reviewed them for safety, effectiveness or quality. Zealthy membership ($39 for the first month, then $135 a month) is billed separately from medication. A prescription is written only if a licensed provider finds it appropriate.